Trilobio

Executive Summary

Trilobio is a San Francisco-based biotechnology company founded in 2020 that aims to democratize laboratory automation through its affordable, integrated platform. The company's core offering combines a modular robotic arm called Trilobot with a user-friendly operating system (Trilobio OS) and an open ecosystem, enabling researchers to design and execute complex protocols without requiring programming skills. By lowering the cost and complexity of automation, Trilobio targets a significant unmet need in life sciences and drug discovery labs, particularly in academic and small-to-medium biotech settings where traditional automation solutions remain prohibitively expensive and technically demanding. The company's open ecosystem approach fosters community collaboration and protocol sharing, potentially accelerating research workflows and reproducibility. While Trilobio operates in a competitive landscape with established players like Opentrons and Tecan, its focus on modularity and no-code operation differentiates it. The company has not disclosed funding details or revenue, but its product addresses the growing demand for accessible lab automation driven by the need for higher throughput and data reproducibility in drug discovery. If successful, Trilobio could become a key enabler of faster and more cost-effective research, though execution risks around adoption, reliability, and scale remain.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Round70% success
• Q4 2026Release of Trilobio OS v2.0 with Enhanced Features60% success
• Q2 2027First Commercial Partnership with a Major Pharma Company30% success